Piramal Pharma Limited - Asset Resilience Ratio
Piramal Pharma Limited (PPLPHARMA) has an Asset Resilience Ratio of 0.73% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PPLPHARMA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2026)
This chart shows how Piramal Pharma Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PPLPHARMA total assets.
Liquid Assets Composition Over Time
This chart breaks down Piramal Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Piramal Pharma Limited for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs1.32 Billion | 0.73% |
| Total Liquid Assets | Rs1.32 Billion | 0.73% |
Asset Resilience Insights
- Limited Liquidity: Piramal Pharma Limited maintains only 0.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Piramal Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Piramal Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082 |
Drug Manufacturers - Specialty & Generic | 0.24% |
Annual Asset Resilience Ratio for Piramal Pharma Limited (2021–2026)
The table below shows the annual Asset Resilience Ratio data for Piramal Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.73% | Rs1.32 Billion ≈ $14.25 Million |
Rs179.65 Billion ≈ $1.94 Billion |
+0.61pp |
| 2025-03-31 | 0.12% | Rs195.60 Million ≈ $2.12 Million |
Rs156.78 Billion ≈ $1.70 Billion |
-0.82pp |
| 2024-03-31 | 0.94% | Rs1.45 Billion ≈ $15.65 Million |
Rs153.12 Billion ≈ $1.66 Billion |
+0.94pp |
| 2023-03-31 | 0.00% | Rs1.00 Million ≈ $10.81K |
Rs145.23 Billion ≈ $1.57 Billion |
-0.42pp |
| 2022-03-31 | 0.42% | Rs543.20 Million ≈ $5.87 Million |
Rs127.97 Billion ≈ $1.38 Billion |
+0.15pp |
| 2021-03-31 | 0.27% | Rs156.40 Million ≈ $1.69 Million |
Rs57.57 Billion ≈ $622.56 Million |
-- |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, devel… Read more